Discover 775 paid clinical trials in Washington, D.C.. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 775
Use of Regional Anesthesia in Hip Arthroscopy
for
Hip Injuries
Location: Washington DC
Sponsor: Georgetown University
Sex: All
Age: 18 - 50
Code: NCT02851888
Recruiting
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Location: Washington D.C. DC, Fairfax VA, Baltimore MD,
Sponsor: Nuvalent Inc.
Sex: All
Age: 18+
Code: NCT06521554
Phase 1, Recruiting
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
for
Solid Tumors
Location: Washington D.C. DC, East Brunswick NJ, New Brunswick NJ,
Sponsor: Exelixis
Sex: All
Age: 18+
Code: NCT07123103
Phase 1, Recruiting
E-Mindfulness Approaches for Living After Breast Cancer
for
Breast Cancer, Depression
Location: Washington D.C. DC, Alexandria VA, McLean VA,
Sponsor: NRG Oncology
Sex: All
Age: 18 - 50
Code: NCT06748222
Phase 3, Recruiting
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Washington D.C. DC, McLean VA, Largo MD,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 0+
Code: NCT06031688
Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Washington D.C. DC, McLean VA, Largo MD,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT06616584
Phase 2, Phase 3, Recruiting
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Washington D.C. DC, McLean VA, Largo MD,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT05642572
Phase 2, Recruiting
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
for
Pulmonary Hypertension Due to Lung Diseases and Hypoxia,
Location: Washington D.C. DC, Falls Church VA, Baltimore MD,
Sponsor: United Therapeutics
Sex: All
Age: 18+
Code: NCT06388421
Recruiting
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
for
ALS
Location: Washington D.C. DC, Philadelphia PA, Hamilton, London,
Sponsor: Amylyx Pharmaceuticals Inc.
Sex: All
Age: 18+
Code: NCT06665165
Phase 1, Recruiting
Pediatric Boot Camp Program
for
Type 1 Diabetes, Children, Only
Location: Washington DC
Sponsor: Georgetown University
Sex: All
Age: 11 - 18
Code: NCT05066893
Recruiting
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
for
Advanced Solid Tumor
Location: Washington D.C. DC, New York NY, Durham NC,
Location: Washington D.C. DC, Richmond VA, Derby CT, New Haven CT,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06465316
Phase 1, Recruiting
A Multi-Institutional Registry for CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)
for
Breast Cancer
Location: Washington DC
Sponsor: Georgetown University
Sex: Female
Age: 50 - 70+
Code: NCT02457117
Recruiting
Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI
for
Catheter-related Infections
Location: Washington DC, Salem VA, Newark NJ, Greenville NC,
Sponsor: Leonard-Meron Biosciences, Inc.
Sex: All
Age: 12+
Code: NCT02901717
Phase 3, Recruiting
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
for
Non-cystic Fibrosis Bronchiectasis
Location: Washington D.C. DC, Williamsburg VA, Philadelphia PA,
Sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Sex: All
Age: 18 - 70+
Code: NCT06559150
Phase 2, Recruiting
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
for
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Location: Washington D.C. DC, Hanover MD, Annapolis MD,